{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:19:24Z","timestamp":1793949564601,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T00:00:00Z","timestamp":1724544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.molmet.2024.102019","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T14:20:39Z","timestamp":1725027639000},"page":"102019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice"],"prefix":"10.1016","volume":"89","author":[{"given":"Leticia","family":"Forny Germano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie L.","family":"Baggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Kin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaj","family":"Rittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiemin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6688-8127","authenticated-orcid":false,"given":"Daniel J.","family":"Drucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.molmet.2024.102019_bib1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology physiology and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metabol"},{"issue":"2","key":"10.1016\/j.molmet.2024.102019_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cmet.2023.12.018","article-title":"Prevention of cardiorenal complications in people with type 2 diabetes and obesity","volume":"36","author":"Drucker","year":"2024","journal-title":"Cell Metabol"},{"issue":"9","key":"10.1016\/j.molmet.2024.102019_bib3","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","article-title":"GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications","volume":"35","author":"Campbell","year":"2023","journal-title":"Cell Metabol"},{"issue":"2","key":"10.1016\/j.molmet.2024.102019_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.molmet.2024.102019_bib5","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.molmet.2024.102019_bib6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.molmet.2024.102019_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.molmet.2024.102019_bib8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.molmet.2024.102019_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J\u00a0Comp Neurol"},{"issue":"9","key":"10.1016\/j.molmet.2024.102019_bib10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.molmet.2024.102019_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.molmet.2024.102019_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","article-title":"Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease","volume":"28","author":"Nowell","year":"2023","journal-title":"Mol Psychiatr"},{"issue":"14","key":"10.1016\/j.molmet.2024.102019_bib13","article-title":"Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway","volume":"10","author":"Li","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.molmet.2024.102019_bib14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study","volume":"44","author":"Vadini","year":"2020","journal-title":"Int J Obes"},{"issue":"7","key":"10.1016\/j.molmet.2024.102019_bib15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol"},{"issue":"S9","key":"10.1016\/j.molmet.2024.102019_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/alz.057848","article-title":"Evaluation of liraglutide in the treatment of Alzheimer's disease","volume":"17","author":"Edison","year":"2021","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.molmet.2024.102019_bib17","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"Norgaard","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.molmet.2024.102019_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.molmet.2024.102019_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112956","article-title":"Rescue of Alzheimer's disease phenotype in a mouse model by transplantation of wild-type hematopoietic stem and progenitor cells","volume":"42","author":"Mishra","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.molmet.2024.102019_bib20","article-title":"Novel object recognition test for the investigation of learning and memory in mice","volume":"126","author":"Lueptow","year":"2017","journal-title":"J\u00a0Vis Exp"},{"issue":"40","key":"10.1016\/j.molmet.2024.102019_bib21","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.molmet.2024.102019_bib22","article-title":"Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice","volume":"96","author":"Seibenhener","year":"2015","journal-title":"J\u00a0Vis Exp"},{"issue":"2","key":"10.1016\/j.molmet.2024.102019_bib23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nprot.2006.116","article-title":"Morris water maze: procedures for assessing spatial and related forms of learning and memory","volume":"1","author":"Vorhees","year":"2006","journal-title":"Nat Protoc"},{"issue":"6","key":"10.1016\/j.molmet.2024.102019_bib24","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2337\/db08-1651","article-title":"Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice","volume":"58","author":"Tschen","year":"2009","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.molmet.2024.102019_bib25","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1096\/fj.201801846R","article-title":"Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer's disease","volume":"33","author":"Qian","year":"2019","journal-title":"Faseb J"},{"issue":"23","key":"10.1016\/j.molmet.2024.102019_bib26","doi-asserted-by":"crossref","first-page":"11591","DOI":"10.18632\/aging.102558","article-title":"Pharmacological inhibition of G9a\/GLP restores cognition and reduces oxidative stress, neuroinflammation and beta-Amyloid plaques in an early-onset Alzheimer's disease mouse model","volume":"11","author":"Grinan-Ferre","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.molmet.2024.102019_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520953041","article-title":"The dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of alzheimer's disease","volume":"35","author":"Maskery","year":"2020","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"1","key":"10.1016\/j.molmet.2024.102019_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metabol"},{"key":"10.1016\/j.molmet.2024.102019_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1146960","article-title":"Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats","volume":"14","author":"Guo","year":"2023","journal-title":"Front Pharmacol"},{"issue":"43","key":"10.1016\/j.molmet.2024.102019_bib30","doi-asserted-by":"crossref","first-page":"11138","DOI":"10.1523\/JNEUROSCI.1238-16.2016","article-title":"TREM2\/DAP12 signal elicits proinflammatory response in microglia and exacerbates neuropathic pain","volume":"36","author":"Kobayashi","year":"2016","journal-title":"J\u00a0Neurosci"},{"issue":"17","key":"10.1016\/j.molmet.2024.102019_bib31","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.15252\/embj.201797397","article-title":"APP mouse models for Alzheimer's disease preclinical studies","volume":"36","author":"Sasaguri","year":"2017","journal-title":"EMBO J"},{"issue":"1\u20132","key":"10.1016\/j.molmet.2024.102019_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0006-8993(00)03186-3","article-title":"Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes","volume":"891","author":"Arendash","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.molmet.2024.102019_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.741923","article-title":"Liraglutide reduces vascular damage, neuronal loss, and cognitive impairment in a mixed murine model of alzheimer's disease and type 2 diabetes","volume":"13","author":"Carranza-Naval","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.molmet.2024.102019_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107813","article-title":"Neuroprotective and restorative properties of the GLP-1\/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease","volume":"162","author":"Salles","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.molmet.2024.102019_bib35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer's disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.molmet.2024.102019_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40478-021-01180-z","article-title":"Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease","volume":"9","author":"Park","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"10.1016\/j.molmet.2024.102019_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020860","article-title":"Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of alzheimer's disease","volume":"22","author":"Paladugu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.molmet.2024.102019_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.111932","article-title":"Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5xFAD mouse model of Alzheimer's disease","volume":"370","author":"An","year":"2019","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.molmet.2024.102019_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1205207","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies","volume":"14","author":"Kong","year":"2023","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.molmet.2024.102019_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.molmet.2024.102019_bib41","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat Metab"},{"issue":"7","key":"10.1016\/j.molmet.2024.102019_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158205","article-title":"Long-term treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has No effect on beta-amyloid plaque load in two transgenic APP\/PS1 mouse models of alzheimer's disease","volume":"11","author":"Hansen","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.molmet.2024.102019_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.139","article-title":"Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals","volume":"4","author":"Bomba","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.molmet.2024.102019_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171271","article-title":"Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP\/PS1 mice","volume":"179","author":"Yang","year":"2024","journal-title":"Peptides"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877824001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877824001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T11:29:59Z","timestamp":1728041399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877824001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":44,"alternative-id":["S2212877824001509"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2024.102019","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2024.102019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102019"}}